Ibudilast

Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Ibudilast
Error creating thumbnail: File missing
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC14H18N2O
Molar mass230.31 g/mol

WikiDoc Resources for Ibudilast

Articles

Most recent articles on Ibudilast

Most cited articles on Ibudilast

Review articles on Ibudilast

Articles on Ibudilast in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Ibudilast

Images of Ibudilast

Photos of Ibudilast

Podcasts & MP3s on Ibudilast

Videos on Ibudilast

Evidence Based Medicine

Cochrane Collaboration on Ibudilast

Bandolier on Ibudilast

TRIP on Ibudilast

Clinical Trials

Ongoing Trials on Ibudilast at Clinical Trials.gov

Trial results on Ibudilast

Clinical Trials on Ibudilast at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ibudilast

NICE Guidance on Ibudilast

NHS PRODIGY Guidance

FDA on Ibudilast

CDC on Ibudilast

Books

Books on Ibudilast

News

Ibudilast in the news

Be alerted to news on Ibudilast

News trends on Ibudilast

Commentary

Blogs on Ibudilast

Definitions

Definitions of Ibudilast

Patient Resources / Community

Patient resources on Ibudilast

Discussion groups on Ibudilast

Patient Handouts on Ibudilast

Directions to Hospitals Treating Ibudilast

Risk calculators and risk factors for Ibudilast

Healthcare Provider Resources

Symptoms of Ibudilast

Causes & Risk Factors for Ibudilast

Diagnostic studies for Ibudilast

Treatment of Ibudilast

Continuing Medical Education (CME)

CME Programs on Ibudilast

International

Ibudilast en Espanol

Ibudilast en Francais

Business

Ibudilast in the Marketplace

Patents on Ibudilast

Experimental / Informatics

List of terms related to Ibudilast

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Ibudilast (AV-411) is an antiinflammatory drug used mainly in Japan, which acts as a phosphodiesterase inhibitor, inhibiting the PDE-4 subtype to the greatest extent,[1] but also showing significant inhibition of other PDE subtypes.[2][3]

Ibudilast has bronchodilator, vasodilator [4] and neuroprotective effects,[5][6] and and is mainly used in the treatment of asthma and stroke.[7] It inhibits platelet aggregation,[8] and may also be useful in the treatment of multiple sclerosis.[9]

Ibudilast crosses the blood-brain barrier and suppreses glial cell activation. This activity has been shown to make ibudilast useful in the treatment of neuropathic pain and it not only enhances analgesia produced by opioid drugs, but also reduces the development of tolerance.[10]


Template:Pharma-stub

References

  1. Huang Z, Liu S, Zhang L, Salem M, Greig GM, Chan CC, Natsumeda Y, Noguchi K. Preferential inhibition of human phosphodiesterase 4 by ibudilast. Life Sciences. 2006 May 1;78(23):2663-8.
  2. Suzumura A, Ito A, Yoshikawa M, Sawada M. Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Research. 1999 Aug 7;837(1-2):203-12.
  3. Gibson LC, Hastings SF, McPhee I, Clayton RA, Darroch CE, Mackenzie A, Mackenzie FL, Nagasawa M, Stevens PA, Mackenzie SJ. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family. European Journal of Pharmacology. 2006 May 24;538(1-3):39-42.
  4. Kishi Y, Ohta S, Kasuya N, Sakita S, Ashikaga T, Isobe M. Ibudilast: a non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall. Cardiovascular Drug Reviews. 2001 Fall;19(3):215-25.
  5. Mizuno T, Kurotani T, Komatsu Y, Kawanokuchi J, Kato H, Mitsuma N, Suzumura A. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology. 2004 Mar;46(3):404-11.
  6. Yoshioka M, Suda N, Mori K, Ueno K, Itoh Y, Togashi H, Matsumoto M. Effects of ibudilast on hippocampal long-term potentiation and passive avoidance responses in rats with transient cerebral ischemia. Pharmacological Research. 2002 Apr;45(4):305-11.
  7. Wakita H, Tomimoto H, Akiguchi I, Lin JX, Ihara M, Ohtani R, Shibata M. Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat. Brain Research. 2003 Nov 28;992(1):53-9.
  8. Rile G, Yatomi Y, Qi R, Satoh K, Ozaki Y. Potentiation of ibudilast inhibition of platelet aggregation in the presence of endothelial cells. Thrombosis Research. 2001 May 1;102(3):239-46.
  9. Feng J, Misu T, Fujihara K, Sakoda S, Nakatsuji Y, Fukaura H, Kikuchi S, Tashiro K, Suzumura A, Ishii N, Sugamura K, Nakashima I, Itoyama Y. Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis. Multiple Sclerosis. 2004 Oct;10(5):494-8.
  10. Ledeboer A, Hutchinson MR, Watkins LR, Johnson KW. Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opinion on Investigational Drugs. 2007 Jul;16(7):935-50.


Template:Phosphodiesterase inhibitors Template:WikiDoc Sources